PSEN2 and HIV-1 infection: More recently, the HVTN505 trial, which used a DNA prime-Ad5 boost immunization regimen, also failed to show any protection with this regimen and had higher numbers of HIV-1 infection in vaccine recipients than the placebo recipients [70] although Ad5 seropositive and uncircumcised men were excluded from the HVTN505 trial.